- Home
- GOVX vs BCTX Comparison
GOVX vs BCTX Comparison
Compare GOVX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- BCTX
- Stock Information
- Founded
- GOVX 2001
- BCTX 2014
- Country
- GOVX United States
- BCTX Canada
- Employees
- GOVX N/A
- BCTX N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- BCTX Health Care
- Exchange
- GOVX Nasdaq
- BCTX Nasdaq
- Market Cap
- GOVX 19.5M
- BCTX 17.5M
- IPO Year
- GOVX N/A
- BCTX N/A
- Fundamental
- Price
- GOVX $1.67
- BCTX $4.42
- Analyst Decision
- GOVX Strong Buy
- BCTX Strong Buy
- Analyst Count
- GOVX 5
- BCTX 1
- Target Price
- GOVX $14.20
- BCTX $32.00
- AVG Volume (30 Days)
- GOVX 569.4K
- BCTX 965.1K
- Earning Date
- GOVX 03-03-2025
- BCTX 03-17-2025
- Dividend Yield
- GOVX N/A
- BCTX N/A
- EPS Growth
- GOVX N/A
- BCTX N/A
- EPS
- GOVX N/A
- BCTX N/A
- Revenue
- GOVX $3,090,161.00
- BCTX N/A
- Revenue This Year
- GOVX N/A
- BCTX N/A
- Revenue Next Year
- GOVX $150.51
- BCTX N/A
- P/E Ratio
- GOVX N/A
- BCTX N/A
- Revenue Growth
- GOVX N/A
- BCTX N/A
- 52 Week Low
- GOVX $1.09
- BCTX $0.35
- 52 Week High
- GOVX $11.18
- BCTX $7.87
- Technical
- Relative Strength Index (RSI)
- GOVX 37.32
- BCTX 61.01
- Support Level
- GOVX $1.50
- BCTX $3.33
- Resistance Level
- GOVX $1.79
- BCTX $5.40
- Average True Range (ATR)
- GOVX 0.13
- BCTX 0.73
- MACD
- GOVX 0.01
- BCTX -0.00
- Stochastic Oscillator
- GOVX 29.82
- BCTX 24.01
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.